Program Type: Midwest CEPAC

Menopause: Vasomotor Symptoms

Dec 2022 | Assessment

Intervontions of Interest: fezolinetant (Astellas Pharma Inc.) Eighty percent of women undergoing menopause experience vasomotor symptoms (VMS). VMS, characterized by hot flashes and night sweats, are thought to be brought on by decreased estrogen levels and increased neurokinin B (NKB) activity acting on the hypothalamus, which regulates body temperature. The change in hypothalamic thermoregulation increases […]

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022 | Assessment

Interventions of Interest: AMX0035 (Amylyx Pharmaceuticals, Inc.) oral edaravone (Mitsubishi Tanabe Pharma Development America, Inc.) The majority of independent appraisal committee voted that the evidence is adequate to demonstrate that both AMX0035 and oral edaravone (in population narrower than its label) provide a net health benefit compared to standard of care. They also determined that […]


Apr 2022 | Assessment

Interventions of Interest: molnupiravir (Merck) PF-07321332/ritonavir (Paxlovid™, Pfizer) fluvoxamine (Investigator initiated) We have deemed this a “special assessment” since this is an early snapshot of emerging agents in the COVID-19 pipeline. Each company has evolving timelines around data availability and potential approvals. Independent appraisal committee voted 11-2 that the evidence is not adequate to demonstrate […]


Nov 2021 | Assessment

Interventions of Interest: Tezepelumab (Tezpire, Amgen/AstraZeneca) ICER’s Evidence Report Findings: Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year. Recommendations for fair access include ensuring that all biologic options be available for […]

Multiple Myeloma

Apr 2021 | Assessment

Interventions of Interest: idecabtagene vicleucel (Abecma®, Bristol-Myers Squibb, bluebird bio) ciltacabtagene autoleucel (Carvykti™, Johnson & Johnson, Legend Biotech Corp) Belantamab mafodotin (Blenrep™, GlaxoSmithKline) The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for […]